Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) is thrilled to announce that it has inked an exclusive license agreement with Takeda, granting them exclusive worldwide rights to develop and research antibody drug conjugates (ADCs) using Innate’s proprietary antibodies targeting an undisclosed target, primarily with a focus on Celiac disease.
Takeda is poised to be the leader of the future, developing, manufacturing, and commercializing innovative products developed from the licensed antibodies. With the potential to revolutionize the industry, Takeda is committed to playing a key role in the success of these products.
Yannis Morel, Ph.D., Executive Vice President, Product portfolio strategy & Business development at Innate Pharma
We are delighted to be partnering with Takeda, a leader in the development of revolutionary treatments across a variety of therapeutic areas. This agreement furthers Innate’s mission by expanding our reach beyond oncology and showcasing the efficacy of our antibody engineering technology in the creation of Antibody Drug Conjugates.
Our proprietary ANKET® technology and antibody platform offer the potential to revolutionize a number of modalities and we are thrilled to be utilizing this cutting-edge technology in our efforts.
Under the terms of our license agreement, Innate is eligible to receive a $5m upfront payment and stands to gain up to $410m in development, regulatory and commercial milestones – plus royalties on potential net sales – if all milestones are achieved within the terms of our agreement. With this agreement, Innate stands to benefit significantly from the commercial success of any product resulting from the license.
About Innate Pharma
At Innate Pharma S.A., we are dedicated to transforming the lives of cancer patients through groundbreaking immunotherapies. Our pioneering ANKET® (Antibody-based NK cell Engager Therapeutics) platform seeks to activate the body’s natural immune system to fight cancer, making us a global leader in the biotechnology space. We are committed to providing innovative solutions for those affected by cancer and are proud to be making a difference.
Innate’s cutting-edge portfolio includes lacutamab, a proprietary program developed for advanced forms of cutaneous and peripheral T cell lymphomas, as well as monalizumab, developed in collaboration with AstraZeneca for non-small cell lung cancer. For even greater efficacy, the company is developing ANKET® multi-specific NK cell engagers to combat a variety of tumor types.
Innate Pharma is a trusted ally to renowned biopharmaceutical companies like Sanofi and AstraZeneca, and esteemed research institutions, to expedite the development of innovative treatments for the betterment of patients. By joining forces with these esteemed entities, Innate Pharma is proud to be making a difference in the lives of those suffering with illness.
Headquartered in the port city of Marseille, France and with a US office in Rockville, Maryland, Innate Pharma is a publicly traded company listed on both Euronext Paris and Nasdaq. With a team of dedicated professionals, the company is committed to developing innovative treatments and therapies to improve the lives of patients around the world.